BIOCYTOGEN PHARMA. H YC1 (F:I54) — Stock Price
BIOCYTOGEN PHARMA. H YC1 (F:I54) is currently trading at €7.40 EUR, up 9.63% today. Over the past 52 weeks, shares have ranged between €2.34 and €7.40. This page tracks BIOCYTOGEN PHARMA. H YC1's live share price on the F exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see BIOCYTOGEN PHARMA. H YC1 market capitalisation.
BIOCYTOGEN PHARMA. H YC1 (I54) Stock Price Chart — Daily History & Trading Volume
The chart below tracks BIOCYTOGEN PHARMA. H YC1's daily closing share price and trading volume on the F exchange over the past year, giving a clear view of recent price momentum and liquidity.
BIOCYTOGEN PHARMA. H YC1 Income Statement — Revenue, Profit & Earnings by Year
BIOCYTOGEN PHARMA. H YC1's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | €1.38 Billion | €980.45 Million | €716.91 Million | €533.88 Million | €354.56 Million |
| Cost of Revenue | €333.22 Million | €218.94 Million | €210.88 Million | €142.13 Million | €107.11 Million |
| Gross Profit | €1.05 Billion | €761.52 Million | €506.03 Million | €391.75 Million | €247.44 Million |
| Research & Development | €438.05 Million | €323.93 Million | €474.37 Million | €699.17 Million | €558.49 Million |
| SG&A | €400.45 Million | €311.35 Million | €349.09 Million | €313.66 Million | €230.15 Million |
| Total Operating Expenses | €1.10 Billion | €830.25 Million | €1.02 Billion | €1.14 Billion | €883.12 Million |
| Operating Income | €278.60 Million | €150.21 Million | €-301.19 Million | €-602.08 Million | €-528.57 Million |
| EBITDA | — | — | — | — | — |
| EBIT | — | — | — | — | — |
| Interest Expense | €71.00 Million | €91.67 Million | €99.84 Million | €56.14 Million | €39.42 Million |
| Income Before Tax | €188.03 Million | €42.94 Million | €-380.16 Million | €-601.35 Million | €-545.64 Million |
| Income Tax Expense | — | — | — | — | — |
| Net Income | €173.20 Million | €33.54 Million | €-382.95 Million | €-601.95 Million | €-545.58 Million |
BIOCYTOGEN PHARMA. H YC1 Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes BIOCYTOGEN PHARMA. H YC1's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | €3.72 Billion | €2.42 Billion | €2.45 Billion | €2.80 Billion | €2.30 Billion |
| Total Current Assets | €2.15 Billion | €816.53 Million | €723.05 Million | €919.30 Million | €874.24 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | — | €8.49 Million | €8.20 Million | €100.00 Million |
| Net Receivables | €300.14 Million | €229.45 Million | €142.21 Million | €107.68 Million | €103.09 Million |
| Inventory | €174.75 Million | €103.56 Million | €89.13 Million | €95.10 Million | €83.27 Million |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | — | — | — | — | — |
| Total Liabilities | €1.54 Billion | €1.58 Billion | €1.66 Billion | €1.65 Billion | €1.05 Billion |
| Total Current Liabilities | €930.31 Million | €534.91 Million | €577.62 Million | €606.05 Million | €446.56 Million |
| Long-term Debt | €192.82 Million | €193.84 Million | €173.91 Million | €52.17 Million | €0.00 |
| Net Debt | — | €20.79 Million | — | — | — |
| Total Stockholder Equity | €2.17 Billion | €834.06 Million | €785.89 Million | €1.15 Billion | €1.25 Billion |
| Retained Earnings | €-1.57 Billion | €-1.75 Billion | €-1.79 Billion | €-1.40 Billion | €-802.32 Million |
BIOCYTOGEN PHARMA. H YC1 Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how BIOCYTOGEN PHARMA. H YC1 generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | €370.25 Million | €211.25 Million | €-76.65 Million | €-303.27 Million | €-365.78 Million |
| Capital Expenditures | €87.82 Million | €37.13 Million | €126.62 Million | €240.27 Million | €198.67 Million |
| Free Cash Flow | €282.43 Million | €174.12 Million | €-203.26 Million | €-543.54 Million | €-564.45 Million |
| Investing Cash Flow | — | — | — | — | — |
| Financing Cash Flow | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | €35.24 Million | €22.64 Million | €30.98 Million | €15.31 Million | €27.75 Million |
| Depreciation | €160.46 Million | €169.18 Million | €182.44 Million | €174.10 Million | €128.10 Million |
| Change in Cash | €1.17 Billion | €-17.90 Million | €-214.74 Million | €130.20 Million | €-230.47 Million |
BIOCYTOGEN PHARMA. H YC1 Earnings History — EPS Actual vs. Analyst Estimates
Track BIOCYTOGEN PHARMA. H YC1's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
Earnings history is not currently available for BIOCYTOGEN PHARMA. H YC1.